What do systematic reviews say?

Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo

The review found no eligible studies for this question.

• Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
  No studies reported this outcome (planned secondary outcome not measured by any study in the review)
  0 studies
  No studies found

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  24 to 70 months
  Only one study (Bonner 2006, 424 participants) comprehensively assessed quality of life using EORTC QLQ-C30 (v3.0) and QLQ-H&N35; no statistically significant difference between groups for global health status or any…
  1 study · 424 participants
  GRADE not reported

Radiotherapy (morning) vs Afternoon radiotherapy

• Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy 2010 · Cochrane All outcomes
  Bjarnason 2009: no statistically significant difference in quality of life scores (data not reported). Morning radiotherapy was associated with significantly less weight loss after 5 months.
  1 study · 216 participants
  GRADE not reported